KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Total Debt (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Total Debt for 13 consecutive years, with $2.1 billion as the latest value for Q4 2025.

  • Quarterly Total Debt rose 42.29% to $2.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.1 billion through Dec 2025, up 42.29% year-over-year, with the annual reading at $2.1 billion for FY2025, 42.29% up from the prior year.
  • Total Debt for Q4 2025 was $2.1 billion at Halozyme Therapeutics, up from $1.5 billion in the prior quarter.
  • The five-year high for Total Debt was $2.1 billion in Q4 2025, with the low at $89.0 million in Q1 2021.
  • Average Total Debt over 5 years is $1.2 billion, with a median of $1.5 billion recorded in 2023.
  • The sharpest move saw Total Debt surged 3014.45% in 2021, then fell 0.46% in 2023.
  • Over 5 years, Total Debt stood at $876.7 million in 2021, then surged by 71.8% to $1.5 billion in 2022, then fell by 0.45% to $1.5 billion in 2023, then rose by 0.44% to $1.5 billion in 2024, then soared by 42.29% to $2.1 billion in 2025.
  • According to Business Quant data, Total Debt over the past three periods came in at $2.1 billion, $1.5 billion, and $1.5 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.